119PREVERSIBLE VERSUS IRREVERSIBLE EGFR TYROSINE-KINASE INHIBITORS FOR NON-SMALL-CELL LUNG CANCER (NSCLC): A PRECLINICAL AND PHARMACOKINETIC COMPARISON


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles